Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

Science

Volumn 286, Issue 5449, 1999, Pages 2528-2531

  Bell, Daphne W ^a   Varley, Jennifer M ^a   Szydlo, Tara E ^a   Kang, Deborah H ^a   Wahrer, Doke C R ^a   Shannon, Kristen E ^a   Lubratovich, Marcie ^a   Verselis, Sigitas J ^a   Isselbacher, Kurt J ^a   Fraumeni, Joseph F ^a   Birch, Julian M ^a   Li, Frederick P ^a   Garber, Judy E ^a   Haber, Daniel A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; GERM LINE; HETEROZYGOSITY; HUMAN; PATHOGENESIS; PENETRANCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLELES; APOPTOSIS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; G1 PHASE; G2 PHASE; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; LI-FRAUMENI SYNDROME; MALE; PEDIGREE; POLYMORPHISM, GENETIC; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SARCOMA; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0033601346     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.286.5449.2528     Document Type: Article

References (58)

1. F. P. Li and J. F. Fraumeni, Ann. Intern. Med. 71, 747 (1969); F. P. Li et al., Cancer Res. 48, 5358 (1988); J. E. Garber et al., Cancer Res. 51, 6094 (1991); J. M. Varley, D. G. R. Evans, J. M. Birch, Br. J. Cancer 76, 1 (1997).
2. F. P. Li and J. F. Fraumeni, Ann. Intern. Med. 71, 747 (1969); F. P. Li et al., Cancer Res. 48, 5358 (1988); J. E. Garber et al., Cancer Res. 51, 6094 (1991); J. M. Varley, D. G. R. Evans, J. M. Birch, Br. J. Cancer 76, 1 (1997).
3. F. P. Li and J. F. Fraumeni, Ann. Intern. Med. 71, 747 (1969); F. P. Li et al., Cancer Res. 48, 5358 (1988); J. E. Garber et al., Cancer Res. 51, 6094 (1991); J. M. Varley, D. G. R. Evans, J. M. Birch, Br. J. Cancer 76, 1 (1997).
4. F. P. Li and J. F. Fraumeni, Ann. Intern. Med. 71, 747 (1969); F. P. Li et al., Cancer Res. 48, 5358 (1988); J. E. Garber et al., Cancer Res. 51, 6094 (1991); J. M. Varley, D. G. R. Evans, J. M. Birch, Br. J. Cancer 76, 1 (1997).
5. D. Malkin et al., Science 250, 1233 (1990); S. Srivastava, Z. Zou, K. Pirollo, W. Blattner, E. H. Chang, Nature 348, 747 (1990).
6. D. Malkin et al., Science 250, 1233 (1990); S. Srivastava, Z. Zou, K. Pirollo, W. Blattner, E. H. Chang, Nature 348, 747 (1990).
7. M. F. Santibanez-Koref et al., Lancet 338, 1490 (1991); J. M. Varley et al., Cancer Res. 57, 3245 (1997).
8. M. F. Santibanez-Koref et al., Lancet 338, 1490 (1991); J. M. Varley et al., Cancer Res. 57, 3245 (1997).
9. M. Hollstein, D. Sidransky, B. Vogelstein, C. C. Harris, Science 253, 49 (1991); C. C. Harris and M. Hollstein, N. Engl. J. Med. 329, 1318 (1993); D. P. Lane, Br. Med. Bull. 50, 582 (1994).
10. M. Hollstein, D. Sidransky, B. Vogelstein, C. C. Harris, Science 253, 49 (1991); C. C. Harris and M. Hollstein, N. Engl. J. Med. 329, 1318 (1993); D. P. Lane, Br. Med. Bull. 50, 582 (1994).
11. M. Hollstein, D. Sidransky, B. Vogelstein, C. C. Harris, Science 253, 49 (1991); C. C. Harris and M. Hollstein, N. Engl. J. Med. 329, 1318 (1993); D. P. Lane, Br. Med. Bull. 50, 582 (1994).
12. L. J. Ko and C. Prives, Genes Dev. 10, 1054 (1996); A. J. Levine, Cell 88, 323 (1997); A. J. Giaccia and M. B. Kastan, Genes Dev. 12, 2973 (1998).
13. L. J. Ko and C. Prives, Genes Dev. 10, 1054 (1996); A. J. Levine, Cell 88, 323 (1997); A. J. Giaccia and M. B. Kastan, Genes Dev. 12, 2973 (1998).
14. L. J. Ko and C. Prives, Genes Dev. 10, 1054 (1996); A. J. Levine, Cell 88, 323 (1997); A. J. Giaccia and M. B. Kastan, Genes Dev. 12, 2973 (1998).
15. L. H. Hartwell and T. A. Weinert, Science 246, 629 (1989); A. M. Carr, Science 271, 314 (1996); T. Weinert, Science 277, 1450 (1997); P. Russell, Trends Biochem. Sci. 23, 399 (1998).
16. L. H. Hartwell and T. A. Weinert, Science 246, 629 (1989); A. M. Carr, Science 271, 314 (1996); T. Weinert, Science 277, 1450 (1997); P. Russell, Trends Biochem. Sci. 23, 399 (1998).
17. L. H. Hartwell and T. A. Weinert, Science 246, 629 (1989); A. M. Carr, Science 271, 314 (1996); T. Weinert, Science 277, 1450 (1997); P. Russell, Trends Biochem. Sci. 23, 399 (1998).
18. L. H. Hartwell and T. A. Weinert, Science 246, 629 (1989); A. M. Carr, Science 271, 314 (1996); T. Weinert, Science 277, 1450 (1997); P. Russell, Trends Biochem. Sci. 23, 399 (1998).
19. N. C. Walworth, S. Davey, D. Beach, Nature 363, 368 (1993); J. B. Allen, Z. Zhou, W. Siede, E. C. Friedberg, S. J. Elledge, Genes Dev. 8, 2401 (1994); T. A. Weinert, G. L. Kiser, L. H. Hartwell, Genes Dev. 8, 261 (1994); H. Murakami and H. Okayama, Nature 374, 817 (1995); N. Walworth and R. Bernards, Science 271, 353 (1996).
20. N. C. Walworth, S. Davey, D. Beach, Nature 363, 368 (1993); J. B. Allen, Z. Zhou, W. Siede, E. C. Friedberg, S. J. Elledge, Genes Dev. 8, 2401 (1994); T. A. Weinert, G. L. Kiser, L. H. Hartwell, Genes Dev. 8, 261 (1994); H. Murakami and H. Okayama, Nature 374, 817 (1995); N. Walworth and R. Bernards, Science 271, 353 (1996).
21. N. C. Walworth, S. Davey, D. Beach, Nature 363, 368 (1993); J. B. Allen, Z. Zhou, W. Siede, E. C. Friedberg, S. J. Elledge, Genes Dev. 8, 2401 (1994); T. A. Weinert, G. L. Kiser, L. H. Hartwell, Genes Dev. 8, 261 (1994); H. Murakami and H. Okayama, Nature 374, 817 (1995); N. Walworth and R. Bernards, Science 271, 353 (1996).
22. N. C. Walworth, S. Davey, D. Beach, Nature 363, 368 (1993); J. B. Allen, Z. Zhou, W. Siede, E. C. Friedberg, S. J. Elledge, Genes Dev. 8, 2401 (1994); T. A. Weinert, G. L. Kiser, L. H. Hartwell, Genes Dev. 8, 261 (1994); H. Murakami and H. Okayama, Nature 374, 817 (1995); N. Walworth and R. Bernards, Science 271, 353 (1996).
23. N. C. Walworth, S. Davey, D. Beach, Nature 363, 368 (1993); J. B. Allen, Z. Zhou, W. Siede, E. C. Friedberg, S. J. Elledge, Genes Dev. 8, 2401 (1994); T. A. Weinert, G. L. Kiser, L. H. Hartwell, Genes Dev. 8, 261 (1994); H. Murakami and H. Okayama, Nature 374, 817 (1995); N. Walworth and R. Bernards, Science 271, 353 (1996).
24. M. N. Boddy, B. Furnari, O. Mondesert, P. Russell, Science 280, 909 (1998); H. D. Lindsay et al., Genes Dev. 12, 382 (1998); Y. Zeng et al., Nature 395, 507 (1998); J. M. Brondello, M. N. Boddy, B. Furnari, P. Russell, Mol. Cell. Biol. 19, 4262 (1999); B. Furnari, A. Blasina, M. N. Boddy, C. H. McGowan, P. Russell, Mol. Biol. Cell 10, 833 (1999).
25. M. N. Boddy, B. Furnari, O. Mondesert, P. Russell, Science 280, 909 (1998); H. D. Lindsay et al., Genes Dev. 12, 382 (1998); Y. Zeng et al., Nature 395, 507 (1998); J. M. Brondello, M. N. Boddy, B. Furnari, P. Russell, Mol. Cell. Biol. 19, 4262 (1999); B. Furnari, A. Blasina, M. N. Boddy, C. H. McGowan, P. Russell, Mol. Biol. Cell 10, 833 (1999).
26. M. N. Boddy, B. Furnari, O. Mondesert, P. Russell, Science 280, 909 (1998); H. D. Lindsay et al., Genes Dev. 12, 382 (1998); Y. Zeng et al., Nature 395, 507 (1998); J. M. Brondello, M. N. Boddy, B. Furnari, P. Russell, Mol. Cell. Biol. 19, 4262 (1999); B. Furnari, A. Blasina, M. N. Boddy, C. H. McGowan, P. Russell, Mol. Biol. Cell 10, 833 (1999).
27. M. N. Boddy, B. Furnari, O. Mondesert, P. Russell, Science 280, 909 (1998); H. D. Lindsay et al., Genes Dev. 12, 382 (1998); Y. Zeng et al., Nature 395, 507 (1998); J. M. Brondello, M. N. Boddy, B. Furnari, P. Russell, Mol. Cell. Biol. 19, 4262 (1999); B. Furnari, A. Blasina, M. N. Boddy, C. H. McGowan, P. Russell, Mol. Biol. Cell 10, 833 (1999).
28. M. N. Boddy, B. Furnari, O. Mondesert, P. Russell, Science 280, 909 (1998); H. D. Lindsay et al., Genes Dev. 12, 382 (1998); Y. Zeng et al., Nature 395, 507 (1998); J. M. Brondello, M. N. Boddy, B. Furnari, P. Russell, Mol. Cell. Biol. 19, 4262 (1999); B. Furnari, A. Blasina, M. N. Boddy, C. H. McGowan, P. Russell, Mol. Biol. Cell 10, 833 (1999).
29. B. Furnari, N. Rhind, P. Russell, Science 277, 1495 (1997); N. Rhind, B. Furnari, P. Russell, Genes Dev. 11, 504 (1997); J. C. Ford et al., Science 265, 533 (1994); A. Lopez-Girona, B. Furnari, O. Mondesert, P. Russell, Nature 397, 172 (1999).
30. B. Furnari, N. Rhind, P. Russell, Science 277, 1495 (1997); N. Rhind, B. Furnari, P. Russell, Genes Dev. 11, 504 (1997); J. C. Ford et al., Science 265, 533 (1994); A. Lopez-Girona, B. Furnari, O. Mondesert, P. Russell, Nature 397, 172 (1999).
31. B. Furnari, N. Rhind, P. Russell, Science 277, 1495 (1997); N. Rhind, B. Furnari, P. Russell, Genes Dev. 11, 504 (1997); J. C. Ford et al., Science 265, 533 (1994); A. Lopez-Girona, B. Furnari, O. Mondesert, P. Russell, Nature 397, 172 (1999).
32. B. Furnari, N. Rhind, P. Russell, Science 277, 1495 (1997); N. Rhind, B. Furnari, P. Russell, Genes Dev. 11, 504 (1997); J. C. Ford et al., Science 265, 533 (1994); A. Lopez-Girona, B. Furnari, O. Mondesert, P. Russell, Nature 397, 172 (1999).
33. Y. Sanchez et al., Science 277, 1497 (1997); C.-Y. Peng et al., Science 277, 1501 (1997).
34. Y. Sanchez et al., Science 277, 1497 (1997); C.-Y. Peng et al., Science 277, 1501 (1997).
35. H. Hermeking et al., Mol. Cell 1, 3 (1997); T. A. Chan, H. Hermeking, C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 401, 616 (1999).
36. H. Hermeking et al., Mol. Cell 1, 3 (1997); T. A. Chan, H. Hermeking, C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 401, 616 (1999).
37. S. Matsuoka, M. Huang, S. J. Elledge, Science 282, 1893 (1998); P. Chaturvedi et al., Oncogene 18, 4047 (1999); A. Blasina et al., Curr. Biol. 14, 1 (1999).
38. S. Matsuoka, M. Huang, S. J. Elledge, Science 282, 1893 (1998); P. Chaturvedi et al., Oncogene 18, 4047 (1999); A. Blasina et al., Curr. Biol. 14, 1 (1999).
39. S. Matsuoka, M. Huang, S. J. Elledge, Science 282, 1893 (1998); P. Chaturvedi et al., Oncogene 18, 4047 (1999); A. Blasina et al., Curr. Biol. 14, 1 (1999).
40. Clinical criteria for diagnosing a family as having LFS are the combination of (i) proband with sarcoma diagnosed under age 45, (ii) first-degree relative with an LFS component tumor (sarcoma, breast cancer, brain tumor, leukemia, or adrenal cancer) diagnosed under age 45, and (iii) first-or second-degree relative with any cancer diagnosed under age 45 or with sarcoma diagnosed at any age. Clinical criteria for LFS-variant are an individual with three separate primary cancers, with the first cancer diagnosed under age 45, or the combination of (i) proband with childhood cancer or LFS component tumor diagnosed under age 45, (ii) first-or second-degree relative with LFS component tumor diagnosed at any age, and (iii) first-or second-degree relative with any cancer diagnosed under age 60 [J. M. Birch et al., Cancer Res. 54, 1298 (1994); C. Eng et al., Cancer Epidemiol. Biomark. Prev. 6, 379 (1997)].
41. Clinical criteria for diagnosing a family as having LFS are the combination of (i) proband with sarcoma diagnosed under age 45, (ii) first-degree relative with an LFS component tumor (sarcoma, breast cancer, brain tumor, leukemia, or adrenal cancer) diagnosed under age 45, and (iii) first-or second-degree relative with any cancer diagnosed under age 45 or with sarcoma diagnosed at any age. Clinical criteria for LFS-variant are an individual with three separate primary cancers, with the first cancer diagnosed under age 45, or the combination of (i) proband with childhood cancer or LFS component tumor diagnosed under age 45, (ii) first-or second-degree relative with LFS component tumor diagnosed at any age, and (iii) first-or second-degree relative with any cancer diagnosed under age 60 [J. M. Birch et al., Cancer Res. 54, 1298 (1994); C. Eng et al., Cancer Epidemiol. Biomark. Prev. 6, 379 (1997)].
42. RNA was isolated from pelleted peripheral blood mononuclear cells, cultured fibroblasts, or EBV-immortalized lymphoblasts using RNA-Stat 60 (Teltest, Friendswood, TX) and reverse transcribed with random hexanucleotides. Overlapping 250-to 350-base pair RT-PCR fragments of the hCHK1 and hCHK2 transcripts were designed to generate homogeneous melting profiles with the Stanford prediction program (available at http:// insertion.stanford.edu/melt.html) and were amplified in nested reactions (primers and conditions are available upon request). Uncloned RT-PCR products were analyzed by DHPLC (Transgenomics, Omaha, NE) to detect mismatched sequences resulting from heterozygous mutations [W. Liu, D. Smith, K. J. Rechtzigel, S. N. Thibodeau, C. D. James, Nucleic Acids Res. 26, 1396 (1998)]. Synthetic mutations were tested for all fragments to ensure optimal analytic conditions. To search for homozygous mutations in cancer cell lines, we mixed equal amounts of PCR products derived from different cell lines to generate detectable mismatches. To search for polymorphic variants in the population, we analyzed EBV-immortalized lymphoblasts from 50 healthy individuals for alterations in the hCHK1 and hCHK2 transcripts. All samples with abnormal chromatography profiles were analyzed by nucleotide sequencing.
43. For automated nucleotide sequencing analysis, uncloned RT-PCR products were sequenced in both directions, with Energy Transfer Dye Primer Chemistry (Amersham Pharmacia Biotech), and analyzed for the presence of heterozygous mutations. Point mutations and small deletions detected in the hCHK2 transcript were confirmed by amplification of genomic DNA and nucleotide sequencing. Nucleotides are numbered from the initiator methionine (GenBank accession number AF086904).
44. Z. Sun, J. Hsiao, D. S. Fay, D. F. Stern, Science 281, 272 (1998).
45. D. P. Cahill et al., Nature 392, 300 (1998).
46. C. J. Sherr, Genes Dev. 12, 2984 (1998).
47. N. Papadopoulos et al., Science 268, 1915 (1995); W. Edelmann et al., Cell 91, 467 (1997); P. O'Connor et al., Cancer Res. 57, 4285 (1997).
48. N. Papadopoulos et al., Science 268, 1915 (1995); W. Edelmann et al., Cell 91, 467 (1997); P. O'Connor et al., Cancer Res. 57, 4285 (1997).
49. N. Papadopoulos et al., Science 268, 1915 (1995); W. Edelmann et al., Cell 91, 467 (1997); P. O'Connor et al., Cancer Res. 57, 4285 (1997).
50. F. Bertoni et al., Genes Chromosomes Cancer 26, 176 (1999).
51. F. Bunz et al., Science 282, 1497 (1998).
52. C. Prives and P. A. Hall, J. Pathol. 187, 112 (1999).
53. R. D. Kolodner, Trends Biochem. Sci. 20, 397 (1995); H. T. Lynch, T. Smyrk, J. F. Lynch, Oncology 55, 103 (1998).
54. R. D. Kolodner, Trends Biochem. Sci. 20, 397 (1995); H. T. Lynch, T. Smyrk, J. F. Lynch, Oncology 55, 103 (1998).
55. P. Nurse, Nature 344, 503 (1990); T. Waldman, C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 381, 713 (1996); A. G. Paulovich, D. P. Toczyski, L. H. Hartwell, Cell 88, 315 (1997).
56. P. Nurse, Nature 344, 503 (1990); T. Waldman, C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 381, 713 (1996); A. G. Paulovich, D. P. Toczyski, L. H. Hartwell, Cell 88, 315 (1997).
57. P. Nurse, Nature 344, 503 (1990); T. Waldman, C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 381, 713 (1996); A. G. Paulovich, D. P. Toczyski, L. H. Hartwell, Cell 88, 315 (1997).
58. We thank L. DiGianni for help with pedigree analysis and S. van den Heuvel for helpful comments on the manuscript. Supported in part by grants from the Dana-Farber-Harvard Gillette Women's Cancer Program (D.A.H.), the Cancer Research Campaign (J.M.B and J.M.V.), and Starr Foundation (F.P.L).